Saby George, MD, FACP, Roswell Park Cancer Institute, shares CARMENA Study Results | Sunitinib Not Inferior to Sunitinib Following Nephrectomy…
Browsing: Kidney
Saby George, MD, FACP, Roswell Park Cancer Institute, explains Checkmate-214 has a Higher Response Rate | 9% of Patients Went…
Saby George, MD, FACP, Roswell Park Cancer Institute, explains Update on Checkmate-214 Study | Approval of Nivolumab & Ipilimumab Combination…
Saby George, MD, FACP, Roswell Park Cancer Institute, shares Checkmate-214 Not for All Kidney Cancer Patients | Study for Advanced…
Ajai Chari, MD, Mt. Sinai discusses Data from MMY1001 Study | Update from Lenalidomide Refractory Subgroup at Annual Meeting 2018
Dr. Jim Brugarolas, Director of the UT Southwestern Kidney Cancer Program, sat down with expert urologist, Dr. Vitaly Margulis, and…